Rosewicz S, Stier U, Brembeck F, Kaiser A, Papadimitriou C A, Berdel W E, Wiedenmann B, Riecken E O
Department of Gastroenterology, Klinikum Benjamin Franklin, Berlin, Germany.
Gastroenterology. 1995 Nov;109(5):1646-60. doi: 10.1016/0016-5085(95)90655-x.
BACKGROUND & AIMS: Advanced pancreatic carcinoma has a dismal prognosis despite extensive chemotherapeutic trials. The aim of this study was to evaluate the role of retinoids as an experimental therapeutic approach for pancreatic cancer.
Four ductal and one acinar pancreatic tumor cell lines were investigated. Growth was determined by cell number and a human tumor clonogenic assay. In vivo growth was assessed by xenografts transplanted into nude mice. Differentiation was characterized by immunofluorescence microscopy and carbonic anhydrase II gene expression. Retinoid receptors were characterized by Northern blotting and reverse-transcriptase polymerase chain reaction.
Retinoid treatment results in a time- and dose-dependent growth inhibition in vitro and in vivo of ductal but not acinar pancreatic tumor cells. Retinoid treatment induces a more differentiated phenotype in ductal tumor cells as shown by morphological criteria and increased expression of carbonic anhydrase II. All pancreatic tumor cell lines expressed a broad panel of cellular retinoid binding proteins and nuclear retinoid receptors. Retinoic acid receptor gamma and cellular retinoic acid binding protein II were found in all retinoid-sensitive ductal tumor cell lines but not in the retinoid-resistant acinar cell lines.
Detailed knowledge of nuclear retinoid receptor expression may provide rational strategies for retinoid treatment of pancreatic cancer.
尽管进行了广泛的化疗试验,但晚期胰腺癌的预后仍然很差。本研究的目的是评估类视黄醇作为胰腺癌实验性治疗方法的作用。
研究了四种导管型和一种腺泡型胰腺肿瘤细胞系。通过细胞数量和人肿瘤克隆形成试验来确定生长情况。通过移植到裸鼠体内的异种移植物评估体内生长情况。通过免疫荧光显微镜和碳酸酐酶II基因表达来表征分化情况。通过Northern印迹法和逆转录聚合酶链反应来表征类视黄醇受体。
类视黄醇治疗在体外和体内对导管型而非腺泡型胰腺肿瘤细胞产生时间和剂量依赖性的生长抑制。类视黄醇治疗可诱导导管型肿瘤细胞出现更分化的表型,这通过形态学标准和碳酸酐酶II表达增加得以体现。所有胰腺肿瘤细胞系均表达多种细胞类视黄醇结合蛋白和核类视黄醇受体。在所有对类视黄醇敏感的导管型肿瘤细胞系中均发现了视黄酸受体γ和细胞视黄酸结合蛋白II,但在对类视黄醇耐药的腺泡型细胞系中未发现。
对核类视黄醇受体表达的详细了解可能为类视黄醇治疗胰腺癌提供合理策略。